GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (NAS:RCEL) » Definitions » Beneish M-Score

RCEL (AVITA Medical) Beneish M-Score : -2.80 (As of Jun. 27, 2025)


View and export this data going back to 2012. Start your Free Trial

What is AVITA Medical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.8 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for AVITA Medical's Beneish M-Score or its related term are showing as below:

RCEL' s Beneish M-Score Range Over the Past 10 Years
Min: -3.53   Med: -2.8   Max: 9.3
Current: -2.8

During the past 13 years, the highest Beneish M-Score of AVITA Medical was 9.30. The lowest was -3.53. And the median was -2.80.


AVITA Medical Beneish M-Score Historical Data

The historical data trend for AVITA Medical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Beneish M-Score Chart

AVITA Medical Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.41 -2.86 -3.53 -1.85

AVITA Medical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.15 -3.31 -3.52 -1.85 -2.80

Competitive Comparison of AVITA Medical's Beneish M-Score

For the Medical Devices subindustry, AVITA Medical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVITA Medical's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Beneish M-Score falls into.


;
;

AVITA Medical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of AVITA Medical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9175+0.528 * 0.994+0.404 * 3.0539+0.892 * 1.4135+0.115 * 0.8611
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8894+4.679 * -0.260208-0.327 * 1.6849
=-2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Total Receivables was $12.15 Mil.
Revenue was 18.514 + 18.406 + 19.546 + 15.195 = $71.66 Mil.
Gross Profit was 15.681 + 16.126 + 16.356 + 13.084 = $61.25 Mil.
Total Current Assets was $47.97 Mil.
Total Assets was $69.56 Mil.
Property, Plant and Equipment(Net PPE) was $13.25 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.44 Mil.
Selling, General, & Admin. Expense(SGA) was $91.01 Mil.
Total Current Liabilities was $22.96 Mil.
Long-Term Debt & Capital Lease Obligation was $44.07 Mil.
Net Income was -13.859 + -11.589 + -16.205 + -15.393 = $-57.05 Mil.
Non Operating Income was -0.791 + -0.315 + -1.068 + 1.611 = $-0.56 Mil.
Cash Flow from Operations was -10.309 + -8.081 + -7.214 + -12.78 = $-38.38 Mil.
Total Receivables was $9.37 Mil.
Revenue was 11.104 + 14.195 + 13.645 + 11.753 = $50.70 Mil.
Gross Profit was 9.591 + 12.399 + 11.532 + 9.549 = $43.07 Mil.
Total Current Assets was $85.99 Mil.
Total Assets was $97.38 Mil.
Property, Plant and Equipment(Net PPE) was $7.57 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.70 Mil.
Selling, General, & Admin. Expense(SGA) was $72.39 Mil.
Total Current Liabilities was $11.86 Mil.
Long-Term Debt & Capital Lease Obligation was $43.83 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(12.148 / 71.661) / (9.367 / 50.697)
=0.16952 / 0.184764
=0.9175

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(43.071 / 50.697) / (61.247 / 71.661)
=0.849577 / 0.854677
=0.994

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (47.967 + 13.25) / 69.556) / (1 - (85.986 + 7.572) / 97.381)
=0.119889 / 0.039258
=3.0539

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=71.661 / 50.697
=1.4135

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.7 / (0.7 + 7.572)) / (1.444 / (1.444 + 13.25))
=0.084623 / 0.098271
=0.8611

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(91.012 / 71.661) / (72.393 / 50.697)
=1.270035 / 1.427954
=0.8894

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((44.073 + 22.956) / 69.556) / ((43.833 + 11.862) / 97.381)
=0.96367 / 0.571929
=1.6849

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-57.046 - -0.563 - -38.384) / 69.556
=-0.260208

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

AVITA Medical has a M-score of -2.80 suggests that the company is unlikely to be a manipulator.


AVITA Medical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


AVITA Medical Business Description

Traded in Other Exchanges
Address
28159 Avenue Stanford, Suite 220, Valencia, Santa Clarita, CA, USA, 91355
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Executives
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David D O'toole officer: CFO 1640 MARENGO STREET, LOS ANGELES CA 90033
Suzanne Crowe director C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
James Corbett director 2 GOODYEAR, IRVINE CA 92618
Jeremy Curnock Cook director TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Donna Shiroma officer: General Counsel C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Cary Guy Vance director 800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043
Michael S Perry director, officer: Chief Executive Officer C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Jan Stern Reed director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Michael Holder officer: Chief Financial Officer 6170 RESEARCH RD., STE 103, FRISCO TX 75034
Kathy M. Mcgee officer: Chief Operating Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Sean Ekins officer: Sr. VP of Finance C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
David Mcintyre officer: Chief Financial Officer SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Erin Liberto officer: Chief Commercial Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Andrew Quick officer: Chief Technology Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 200, VALENCIA CA 91355